Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study
Titel:
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study
Auteur:
Silberstein, Stephen Diamond, Merle Hindiyeh, Nada A. Biondi, David M. Cady, Roger Hirman, Joe Allan, Brent Pederson, Susan Schaeffler, Barbara Smith, Jeff